SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2026

SEGMENT INFORMATION

SEGMENT INFORMATION

NOTE 8 – SEGMENT INFORMATION

a. The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results on a consolidated basis based on net income (losses).

b. Segment information:

	Six Months Ended June 30,				Three Months Ended June 30,
(U.S. dollars in thousands)	2026		2025		2026		2025
Revenues from customers	$	53,646	$	25,771	$	19,896	$	15,658
Less:
Employee salaries and related expenses		14,352		10,649		7,655		5,444
Sub-contractors expense		8,340		7,463		3,899		4,773
Interest expense		-		-		-		-
Interest income		(848)		(528)		(660)		(272)
Depreciation		810		706		406		360
R&D grant		(2,100)				(2,100)
Other segment expenses, net*		7,091		10,552		5,836		4,692
Income (loss) before taxes on income		26,001		(3,071)		4,860		661
Taxes on income		3,907		384		1,083		497
Segment net income (loss)	$	22,094	$	(3,455)	$	3,777	$	164

* Other expenses included in net income include raw materials, rent, and utilities, and others.

c. The following table summarizes the Company’s disaggregation of revenues:

	Six Months Ended June 30,				Three Months Ended June 30,
(U.S. dollars in thousands)	2026		2025		2026		2025
Gaucher disease:
Pfizer (Ireland)	$	5,731	$	12,626	$	4,279	$	5,647
Fiocruz (Brazil)	$	3,968	$	3,016	$	1,514	$	-
Fabry disease:
Chiesi (Italy)	$	17,548	$	9,793	$	14,035	$	9,793
Total revenues from selling goods	$	27,247	$	25,435	$	19,828	$	15,440
Revenues from license and R&D services	$	26,399	$	336	$	68	$	218

d. Long lived assets are located in Israel.